|
Ceftizoxime sodium
Ceftizoxime sodium (Cefizox)
Ceftizoxime sodium
(sef-tih-
ZOX-eem)
Pregnancy Category: B
Cefizox
(Rx)
Classification:
Cephalosporin, third-generation
See Also:
See also
Anti-Infectives and
Cephalosporins
[.
]
Action/Kinetics:
t
1/2: Approximately 1-2 hr.
Peak serum levels after 1 g IV: 60-87 mcg/mL. Approximately 80% excreted unchanged in the urine.
Uses:
(1) Lower respiratory tract infections due to
Streptococcus species (including
S. pneumoniae, but excluding enterococci),
Klebsiella species,
Proteus mirabilis, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains),
Staphylococcus aureus (penicillinase/nonpenicillinase-producing),
Serratia species,
Enterobacter species, and
Bacteroides species. (2) UTIs due to
S. aureus, E. coli, Pseudomonas species (including
P. aeruginosa),
P. mirabilis, P. vulgaris, Providencia rettgeri, Morganella morganii, Klebsiella species,
Serratia species (including
S. marcescens), and
Enterobacter species. (3) Uncomplicated cervical and urethral gonorrhea due to
N. gonorrhoeae. (4) PID due to
N. gonorrhoeae, E. coli, or
S. agalactiae. (5) Intra-abdominal infections due to
E. coli, S. epidermidis, Streptococcus species (excluding enterococci),
Enterobacter species,
Klebsiella species,
Bacteroides species (including
B. fragilis) and anaerobic cocci (including
Peptococcus and
Peptostreptococcus species). (6) Septicemia due to
Streptococcus species (including
S. pneumoniae, but excluding enterococci),
S. aureus,
E. coli, Bacteroides species (including
B. fragilis),
Klebsiella species, and
Serratia species. (7) Skin and skin structure infections due to
S. aureus, S. epidermidis, E. coli, Klebsiella species,
Streptococcus species (including
S. pyogenes, but excluding enterococci),
P. mirabilis, Serratia species,
Enterobacter species,
Bacteroides species (including
B. fragilis) and anaerobic cocci (including
Peptococcus and
Peptostreptococcus species). (8) Bone and joint infections due to
S. aureus, Streptococcus species (excluding enterococci),
P. mirabilis, Bacteroides species (including B. fragilis) and anaerobic cocci (including
Peptococcus and
Peptostreptococcus species). (9) Meningitis due to
H. influenzae and limited use for
S. pyogenes.
Additional Side Effects:
Transient increased levels of eosinophils, AST, ALT, and CPK have been seen in children over 6 months of age.
How Supplied:
Injection: 1 g/50 mL, 2 g/50 mL;
Powder for injection: 500 mg, 1 g, 2 g, 10 g
Dosage
?IM, IV
Uncomplicated urinary tract infections.
Adults: 0.5 g q 12 hr IM or IV.
Severe or resistant infections.
Adults: 1 g q 8 hr or 2 g q 8-12 hr IM or IV.
Life-threatening infections.
Adults: Up to 3-4 g q 8 hr IV.
Pelvic inflammatory disease.
2 g q 8 hr IV (doses up to 2 g q 4 hr have been used).
Infections at other sites.
Adults: 1 g q 8-12 hr IM or IV.
?IV
Uncomplicated gonorrhea.
Adults: 1 g as a single dose
IM.
Use in children.
Pediatric, over 6 months: 50 mg/kg q 6-8 hr up to 200 mg/kg/day (not to exceed the maximum adult dose).
Impaired renal function.
Initial, IM, IV: 0.5-1 g;
then, use maintenance schedule in package insert. |
